LIVN vs. HAE, NTUS, MASI, TMDX, ITGR, CNMD, INMD, SLNO, BLFS, and ZYXI
Should you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include Haemonetics (HAE), Natus Medical (NTUS), Masimo (MASI), TransMedics Group (TMDX), Integer (ITGR), CONMED (CNMD), InMode (INMD), Soleno Therapeutics (SLNO), BioLife Solutions (BLFS), and Zynex (ZYXI). These companies are all part of the "medical" sector.
LivaNova (NASDAQ:LIVN) and Haemonetics (NYSE:HAE) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.
LivaNova has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.
Haemonetics received 3 more outperform votes than LivaNova when rated by MarketBeat users. However, 68.84% of users gave LivaNova an outperform vote while only 60.89% of users gave Haemonetics an outperform vote.
97.6% of LivaNova shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 0.3% of LivaNova shares are owned by insiders. Comparatively, 1.8% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Haemonetics has a net margin of 8.98% compared to LivaNova's net margin of -2.68%. Haemonetics' return on equity of 22.25% beat LivaNova's return on equity.
LivaNova presently has a consensus target price of $66.20, indicating a potential upside of 24.02%. Haemonetics has a consensus target price of $108.67, indicating a potential upside of 27.05%. Given Haemonetics' stronger consensus rating and higher possible upside, analysts clearly believe Haemonetics is more favorable than LivaNova.
In the previous week, LivaNova had 7 more articles in the media than Haemonetics. MarketBeat recorded 13 mentions for LivaNova and 6 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.00 beat LivaNova's score of 0.72 indicating that Haemonetics is being referred to more favorably in the news media.
Haemonetics has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.
Summary
Haemonetics beats LivaNova on 14 of the 17 factors compared between the two stocks.
Get LivaNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LivaNova Competitors List
Related Companies and Tools
